SCHEMBL3014290

SCHEMBL3014290

Clc1ccn2c(-c3ccnc(Cl)c3)cnc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.52
FGFR3 P22607 4/20 0.52
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
HPGD P15428 1/20 0.44
BACE1 P56817 1/20 0.43
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA3 P34903 1/20 0.42
FLT3 P36888 6/20 0.42
DYRK3 O43781 1/20 0.40
CCNT1 O60563 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
CDK5 Q00535 1/20 0.40
DYRK1A Q13627 1/20 0.40
CDK5R1 Q15078 1/20 0.40
DYRK2 Q92630 1/20 0.40
DYRK1B Q9Y463 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652571 0.92 KDR (0.46) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3657771 0.89 KDR (0.50) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3031962 0.84 KDR (0.51) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL16964942 0.84 KDR (0.64) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3026044 0.82 KDR (0.54) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3026012 0.81 KDR (0.55) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3323604 0.81 FLT3 (0.66) KDRFGFR3FLT3
SCHEMBL3034596 0.80 FLT3 (0.51) KDRFGFR3PRMT5WDR77GABRG2
SCHEMBL10174894 0.80 KDR (0.71) KDRFGFR3PRMT5WDR77HPGD
SCHEMBL3031805 0.79 PRMT5 (0.47) PRMT5WDR77FLT3DYRK3CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367662-B2 Organic compounds NOVARTIS AG (CH) 2013-02-05 US disclosed
EP-2212323-B1 IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS NOVARTIS AG (CH) 2012-08-15 EP disclosed
US-20100210641-A1 Organic Compounds NOVARTIS AG (CH) 2010-08-19 US disclosed
EP-2212323-A2 IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050183-A2 IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS NOVARTIS AG (CH) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210641-A1 Organic Compounds ALK, ACVR1, ACVRL1 KDR 372/4885FGFR3 32/4885PRMT5 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.